

KFIN/GXP/JUN/2022

Date:04/07/2022

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals
Limited Dr. Annie Besant Road
Worli ,Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended June 30,2022.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended June 30, 2022.

Description of Complaint	Opening Balance as on 01.04.2022	Received during the Period 01.04.2022 to 30.06.2022	Attended/Resolved during the Period 01.04.2022 to 30.06.2022	Pending as on 30.06.2022
Non-receipt of Dividend	NIL	11	11	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of share certificates	NIL	NIL	NIL	NIL
SEBI	NIL	10	10	NIL
Stock Exchange	NIL	06	06	NIL
Total	NIL	27	27	NIL

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Limited



Rajitha Cholleti